Last reviewed · How we verify
GnP
GnP is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
GnP is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes, Reduction of major adverse cardiovascular events in patients with established cardiovascular disease or multiple cardiovascular risk factors.
At a glance
| Generic name | GnP |
|---|---|
| Sponsor | West China Hospital |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
By inhibiting SGLT2, GnP reduces glucose reabsorption in the kidneys, leading to a decrease in blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes, as it helps to lower HbA1c levels and reduce the risk of cardiovascular events.
Approved indications
- Treatment of type 2 diabetes
- Reduction of major adverse cardiovascular events in patients with established cardiovascular disease or multiple cardiovascular risk factors
Common side effects
- Increased risk of diabetic ketoacidosis
- Genital amputations
- Increased risk of acute kidney injury
- Increased risk of hypotension
- Increased risk of urinary tract infections
Key clinical trials
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (PHASE3)
- Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2)
- Registry for Duchenne and Becker Muscular Dystrophy
- A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2) (PHASE3)
- A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (PHASE1, PHASE2)
- Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (PHASE3)
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC (PHASE2)
- A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |